Sun BioPharma, Inc. Provides an Update on Ongoing Front-Line Pancreatic Cancer Clinical Trial

UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, provides an update on the Company’s current clinical trial.

Following successful conclusion of the first SBP-101 dose-escalation study in heavily pretreated pancreatic cancer patients that showed SBP-101 could be administered safely as monotherapy, a second Phase 1 safety study entitled, “SBP-101 Administered in Combination with Gemcitabine and Nab-paclitaxel in Newly Diagnosed Patients with Metastatic Pancreatic Ductal Adenocarcinoma” was undertaken to evaluate the addition of SBP-101 to front line gemcitabine and nab-paclitaxel treatment. Two of 3 planned cohorts receiving the combination have completed enrollment.

Learn more about Sun BioPharma, Inc. Provides an Update on Ongoing Front-Line Pancreatic Cancer Clinical Trial.